Most common Rheumatology denials
Denials you probably recognize
Biologic therapy denied -- conventional DMARDs not failed
Advanced imaging denied for joint assessment
Infusion therapy denied -- self-injectable preferred
JAK inhibitor denied -- biologic not failed first
Specialty labs denied as not medically necessary
Sound familiar? WinTheP2P generates a structured response script for each of these scenarios in 60 seconds.
Rheumatology-specific P2P strategy
What wins rheumatology P2P calls
Reference ACR guidelines for RA, PsA, and lupus treatment algorithms
Document DAS28 scores, joint counts, and inflammatory markers over time
For biologic step therapy, list each DMARD trialed with doses, durations, and specific reasons for failure
Emphasize irreversible joint damage risk from treatment delays
Cite treat-to-target strategy and guideline-recommended escalation timelines
Key criteria sources
Guidelines that matter for Rheumatology
When speaking with a medical director during a P2P call, referencing the correct clinical criteria is what separates a successful appeal from a denied one. For rheumatology, the key sources are:
ACR Guidelines, EULAR Recommendations
WinTheP2P automatically references these criteria when generating your rheumatology P2P prep scripts.